DEFR14A: Masimo Faces Proxy Battle as Politan Seeks Board Control Amidst Strategic Review

Masimo is urging stockholders to reject Politan's nominees at the upcoming annual meeting, citing concerns over the activist investor's potential influence on the company's innovation and strategic direction.

Summary

• Masimo's revised proxy statement details the postponement of its 2024 Annual Meeting to September 19, 2024, due to a request from Politan Capital Management to set a new record date.
• The company is urging stockholders to vote for its director nominees, Christopher Chavez and Joe Kiani, and against the Politan Group's proposal to repeal any bylaw amendments adopted by the board without stockholder approval.
• Masimo highlights its recent successes, including FDA clearances for innovative products and record-breaking sales in certain product lines, despite challenges in the post-COVID market.
• The board is evaluating a potential separation of the consumer business to unlock value for stockholders.
• The proxy statement also outlines the board's responsiveness to stockholder feedback, including declassifying the board and enhancing corporate governance practices.
• The company is engaged in ongoing litigation with Politan, alleging violations of securities laws and breaches of fiduciary duty.
• Masimo is also in discussions with a potential JV partner regarding a potential transaction involving the company's consumer business, with a non-binding term sheet confirmation indicating a purchase price range of $850 million to $950 million.
• The company is emphasizing the risks of ceding control to Politan, which holds less than 9% of the outstanding shares, and highlighting what it views as obstructionist behavior by Politan's representatives on the board.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While highlighting positive achievements and future plans, it also acknowledges challenges and risks associated with the proxy contest and strategic review.

Positives

• Masimo achieved record contracting year with hospital customers in 2023.
• The company secured FDA clearances for innovative products like Masimo Opioid Halo and Radius VSM.
• Hearables and wearables revenue grew by more than 90% to reach $90 million.
• The board is evaluating a potential separation of the consumer business to unlock value for stockholders.
• The company has implemented several corporate governance enhancements in response to stockholder feedback, including declassifying the board and adding a lead independent director.

Negatives

• Masimo is facing a proxy contest from Politan Capital Management, which is seeking to elect two additional directors to the board.
• The company is engaged in ongoing litigation with Politan, alleging violations of securities laws and breaches of fiduciary duty.
• 2023 financial performance fell below the objective performance goals established under our compensation program.
• The company did not meet the minimum performance threshold required in order to payout the annual cash incentive bonus to any NEOs.

Risks

• The proxy contest with Politan threatens Masimo's innovation and culture.
• Ceding control to Politan could negatively impact relationships with customers and partners.
• The loss of key talent could hinder Masimo's long-term growth potential.
• The company is facing potential legal and financial risks associated with the ongoing litigation with Politan.
• The potential separation of the consumer business could present challenges in terms of capitalization and access to assets.

Future Outlook

Masimo plans to announce new product innovations in the coming months that it believes will transform patient monitoring, and is working on a new kind of hearing aid based on its revolutionary Masimo AAT.

Management Comments

• Joe Kiani: 'Masimo has a great history of solving the unsolvable, and I am confident we are well positioned to continue bringing life -changing products to market.'
• Joe Kiani: 'This latest proxy contestwhich threatens to hand control of Masimo to an activist investorputs both our recent momentum and Masimos spirit of innovation and success at risk.'
• Craig Reynolds: 'We expect that this separation will continue to provide long -term growth opportunities for the consumer business while improving the long -term profitability and earnings power of the healthcare business.'

Industry Context

The announcement comes amid increasing activist investor activity in the healthcare and medical device industries, with firms seeking to influence company strategy and governance.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards.
• The document does not contain specific comparisons to comparable companies.
• The document does not contain specific comparisons to comparable projects.
• The document does not contain specific comparisons to comparable results.

Legal Proceedings

• Masimo has commenced litigation against Politan, including Mr. Koffey and Ms. Brennan, in the United States District Court for the Central District of California seeking, among other things, an order declaring that Politans proxy materials for the 2024 Annual Meeting violate Section 14(a) of the Securities Exchange Act of 1934, as amended, an order enjoining Politan from voting any proxies received by means of Politans misleading proxy material, an order invalidating any proxies Politan or other persons acting in concert with it obtained pursuant to the misleading proxy material and an injunction requiring Politan to correct material misstatements and omissions in Politans proxy materials for the 2024 Annual Meeting.
• On July 17, 2024, despite Politans multiple requests that the Company move the record date for the 2024 Annual Meeting, Politan commenced litigation against the Company in the Court of Chancery of the State of Delaware alleging that Messrs. Kiani, Reynolds and Chapek breached their fiduciary duties to the Company by moving the date of the 2024 Annual Meeting.

Related Party Transactions

• Masimo is party to a cross-licensing agreement with Willow Laboratories, Inc., of which Joe Kiani is the Chairman and CEO, and made royalty payments of approximately $19.2 million in fiscal 2023.
• Masimo is party to a services agreement with Willow Laboratories, Inc., and received approximately $0.5 million for general and administrative services rendered in fiscal 2023.
• Masimo leases office space from Willow Laboratories, Inc., and recognized approximately $1.2 million of lease income in fiscal 2023.
• Masimo made approximately $1.0 million in cash contributions to the Masimo Foundation for Ethics, Innovation and Competition in Healthcare, of which Joe Kiani is the Chairman.
• Masimo incurred $1.5 million in marketing expenses payable to Like Minded Media Ventures, of which Joe Kiani is the co-founder and a member of the Board of Directors.

Stakeholder Impact

• The proxy contest could impact shareholders by influencing the company's strategic direction and potentially affecting its stock price.
• Employees may be affected by changes in company culture and management resulting from the proxy contest.
• Customers and partners could be impacted by changes in Masimo's relationships and innovation strategy.
• The potential separation of the consumer business could impact stakeholders of both the resulting companies.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting on September 19, 2024.
• The board will continue to evaluate the potential separation of the consumer business.
• The company will continue to pursue discussions with the potential JV partner regarding a potential transaction involving the consumer business.

Key Dates

Keywords

proxy contest, Politan Capital, board election, corporate governance, executive compensation, annual meeting, Masimo, director nominees